Download file (7.7 MB)
Download as zip (6.71 MB)

Collection

Citation

Description:

In recent years, cancer vaccines that intend to specifically initiate host immune responses against cancer have achieved some clinical success. Delivery of vaccines with traditional needles is usually associated with the risk of infection and poor patient compliance. The development of needle-free vaccines may overcome these limitations. In this work, a needle-free patch is designed for effective cancer vaccination using a fluorine chain-modified cationic polymer, fluorinated chitosan (FCS), which is able to transdermatically deliver the antigen to antigen-presenting cells in the skin. Specifically, a transdermal carrier, FCS, and model antigen ovalbumin (OVA) can self-assemble into nanoparticles, which can reversibly open the tight junction-associated proteins of epithelial cells and penetrate across the epidermis. The needle-free cancer vaccine patch is fabricated by mixing FCS-OVA nanoparticles with the US Food and Drug Administration-approved immune adjuvant imiquimod (R837) in blank cream. Such a needle-free cancer vaccine can generate robust immune responses to protect mice against ovalbumin-expressing melanoma (B16-OVA). Compared to traditional intradermal injection, needle-free cancer vaccines achieved an even more efficient protection effect against B16-OVA cancer cells. This work indicated that the novel needle-free cancer vaccine may provide a compelling technology for simple and safe vaccination, which may help to increase vaccination coverage.

Rights:

• In Copyright
  

  This is the peer reviewed version of the following article: Z. Xiao, G. Li, D. Deng, T. Wei, G. Chen, H. Tao, Y. Chao, B. Liu, Q. Li, Y. Yang, Z. Liu, Q. Chen, Noninvasive Needle-Free Cancer Vaccine Cream Patch Based on Fluorinated Chitosan. Adv. Funct. Mater. 2024, 34, 2314022, which has been published in final form at https://doi.org/10.1002/adfm.202314022. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.

Keyword: cancer immunotherapy, fluorinated chitosan, needle-free vaccines, transdermal delivery

Date published: 2023-12-22

Publisher: Wiley-Blackwell

Journal:

• ADVANCED FUNCTIONAL MATERIALS (ISSN: 1616301X) vol. 34 issue. 17 p. 1-12

Funding:

Manuscript type: Author's version (Accepted manuscript)

MDR DOI: https://doi.org/10.48505/nims.4888

First published URL: https://doi.org/10.1002/adfm.202314022

Related item:

Other identifier(s):

Contact agent:

Updated at: 2024-12-22 12:30:29 +0900

Published on MDR: 2024-12-22 12:30:30 +0900